
Sign up to save your podcasts
Or


In Episode 36, Greg and Rob provide updates on recent 340B news around state legislation, manufacturer restrictions, and HRSA's decision to not appeal the Genesis case court ruling. They also provide insight and thoughts around the HRSA data request list item 2, the covered entity eligibility documentation.
Also, if you are at 340B Winter Coalition, make sure to come see the team at Booth 611.
For our last episode of 2023, Greg and Rob reviewed hot topics impacting 340B covered entities from the past year.
In this episode, Greg and Rob are joined by Spendmend colleague Cat Eriksen (16:11) to discuss the importance of self-auditing as part of a 340B covered entity’s overall compliance strategy. They’ll talk about HRSA standards around self-auditing, how some hospitals and clinics struggle to prioritize this effort, and why seeking external support to address self-auditing needs might be a good approach for some.
But first, the guys share additional thoughts on the recent Genesis case.
SpendMend is at ASHP Midyear, stop by and see some members of our team at Booth 1500.
Also, don’t forget to register for our next webinar: https://attendee.gotowebinar.com/register/6765415327956894816?source=340B+Unscripted
In this episode, Rob and Greg share thoughts from the recent federal court ruling on the Genesis v Becerra case, which focuses on patient definition. Additionally, they catch up on manufacturer restriction changes and some developments from recent Senate HELP Committee 340B inquiries.
If you are attending the ASHP Clinical Midyear meeting in Anaheim, make sure to stop by booth 1500 to see us!
This episode is the first part of a series of recordings we are putting together to review the HRSA data request list (DRL). Rob and Greg discuss DRL item #1 – 340B Policies and Procedures. They’ll review the types of operations that HRSA expects to see outlined in a covered entity’s 340B policies and share some insights into how to manage these documents.
HRSA audit readiness and a detailed overview of the DRL will be the subject of our next SpendMend Pharmacy Webinar in December 2023. Look for more information on registering for this webinar on our social media pages.
Have a suggested podcast topic? Email us at [email protected] with your ideas.
In this bonus episode, Rob and Greg review the HRSA notice published on October 27 that addresses the immediate use of 340B drugs in unregistered locations and some hospital considerations in response to the update.
In this episode, Rob is pitted against ChatGPT to answer 340B-related FAQs, including topics like child site registration, GPO prohibition, and HRSA audit findings (17:29). In the intro, Greg and Rob catch up on revised contract pharmacy restrictions and thoughts on recent manufacturer inquiries that 340B entities have been receiving.
Email us questions, comments, or suggested podcast topics at [email protected]!
Rich Bucher, one of the co-founders of Turnkey Pharmacy Solutions, makes a long-awaited appearance on the podcast with Greg and Rob. Rich and Rob share anecdotes from their early days getting involved in external 340B support (23:26). Rich also shares some thoughts on 340B topics like GPO Prohibition mitigation strategies (39:13), what to make of the FAQ 4301 developments earlier this year (49:58) and opinions on recent state-enacted laws addressing contract pharmacy provisions (57:49).
In the intro, Greg, Rob, and Rich get caught up on manufacturer restrictions and react to inquiries sent to 340B hospitals from the Senate HELP Committee.
Also, don’t forget to register for an upcoming SpendMend webinar focusing on innovative pharmacy supply chain management:
https://attendee.gotowebinar.com/register/677788879648187232?source=340B+Unscripted
In this episode, Greg and Rob are joined by healthcare attorney Jeff Davis, to discuss how the Medicare drug pricing provisions in the IRA will impact 340B providers. They’ll go over CMS billing modifier requirements (15:27), share opinions on the financial impact covered entities might experience (38:02), and how various legal challenges to the IRA by the pharma industry may play out (56:29). They also add some insights around CMS’s proposed Part B payment remedy (1:01:03).
In the intro, Rob catches Greg up on new manufacturer restrictions, and some recent HRSA audit experience related to interpreting data request list (DRL) revisions, and shares some commentary on the current House E&C subcommittee hearing on proposed drug shortage legislation.
Email us questions, thoughts, and ideas for podcast topics at [email protected]!
Rob and Greg continue their conversation with health care attorney and 340B expert Emily Cook (21:05). They discuss thoughts on the CMS Medicare Part B remedy, provide some commentary on the Inflation Reduction Act (IRA) and its intersection with 340B covered entities, and address an issue that could impact hospital DSH eligibility in the future.
In the intro, Greg and Rob are joined by SpendMend colleague Jennifer Hagen and catch up on recent 340B developments, including updates on manufacturer restrictions, follow-up from a prior question about CAR-T therapy, as well as Spendmend’s reference within an amicus brief filed in the Genesis case. Finally, the team recaps recent changes discovered in the HRSA audit data request list (DRL).
If you have any questions or topic suggestions, please email [email protected].